JP Morgan Chase
RYTM icon

JP Morgan Chase’s Rhythm Pharmaceuticals RYTM Stock Holding History

JP Morgan Chase’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$4.33M – 7703
2024
Q1 		$4.33M Buy
+100,000
New +$4.38M ﹤0.01% 3214

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

JP Morgan Chase's RYTM Position: Q2 2026 in Review

JP Morgan Chase increased its Rhythm Pharmaceuticals (RYTM) stake by 71% in Q2 2026, buying an estimated $99.4M and bringing the position to 2,652,746 shares worth $292M. The position accounts for 0.02% of the portfolio, ranked #618.

JP Morgan Chase first reported a position in RYTM in Q4 2017 and has held it in 35 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • JP Morgan Chase held 2,652,746 shares of Rhythm Pharmaceuticals worth $292M as of Q2 2026.
  • JP Morgan Chase bought 1,099,102 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $99.4M.
  • Rhythm Pharmaceuticals made up 0.02% of JP Morgan Chase's portfolio in Q2 2026, its #618 holding.
  • JP Morgan Chase first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.